Compare Natera Inc. Common Stock (NTRA) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Trade Desk Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Trade Desk Inc trades at $12.12 (market cap $5.75B). The key difference: Natera Inc. Common Stock is far larger — about 9.9× Trade Desk Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Trade Desk Inc for 73 Days on average.
| NTRA | TTD | |
|---|---|---|
Market Cap | $57.03B | $5.75B |
Volume | 1,131,157 | 15,249,283 |
Sector | Health | Media |
52-Week High | $425.64 | $54.13 |
52-Week Low | $179.42 | $11.92 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $56.18B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
The Trade Desk (TTD) trades at $12.18, down 68% year-to-date amid slowing revenue growth and increased competition. Technical indicators show bearish momentum with mixed earnings performance, beating estimates in Q2 but missing in Q1. The company maintains strong profitability margins (76.9% gross margin) but faces headwinds from Amazon and other tech giants expanding into ad-tech. Recent workforce reductions and downward revenue guidance reflect operational challenges.
Despite current pressures, TTD maintains leadership in programmatic advertising with solid cash flow generation. Analyst consensus suggests 20% upside to the $14.68 price target, though competitive threats and slowing growth present significant risks. The stock's valuation appears reasonable with P/E of 0.14 and P/S of 0.02, but investors should weigh the company's ability to defend its market position against larger competitors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
